Published in Blood Weekly, August 5th, 2004
As a result, the company expects to report fully diluted earnings per share in a range of $0.33 to $0.35, or $0.05 to $0.07 more than the current consensus estimate and $0.13 to $0.15 better than the second quarter of last year.
Ventana develops, manufactures, and markets instrument/reagent systems that automate slide preparation and staining in clinical histology and drug discovery laboratories.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.